PNV.AU Polynovo Ltd
- Market cap
- AUD 625M
- P/E
- 90.5x
- P/B
- 6.89x
- ROE
- 8.1%
- Dividend yield
- -
- Fundamental score
- 2.1/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PNV.AU undervalued?
Graham numberThe Graham number of Polynovo Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Polynovo Ltd fundamental analysis
10 of 22 checks passedROE 0/2
Low return on equity (8.1%), below 10%.
ROA 1/1
Return on assets (5.5%) is above the industry median (-51.4%).
Profit Consistency 1/2
Profitable for 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-44.4%) is below the industry median (-5.3%).
Revenue Growth 2/2
Revenue grew 30.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (19.4%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 11.4x against interest expense, well covered.
PE vs Market 0/1
PE (90.5x) is above the market median (15.0x).
PE vs Industry 0/1
PE (90.5x) is above the industry median (16.3x).
PBV 0/1
Price to book (6.9x) is above the industry median (4.4x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 623.9, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Polynovo Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Polynovo Ltd
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, Hong Kong, and China. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn; NovoSorb MTX for burns, chronic, trauma, and surgical wounds; and hernia repair, plastics and reconstructive device p…
Full company profilePolynovo Ltd financial statements
Polynovo Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 3.62M | 6.55M | 14.0M | 22.2M | 29.2M | 41.4M | 65.2M | 103M | 127M | 144M |
| Gross Profit | 2.20M | 2.12M | 9.50M | 5.01M | 7.83M | 16.2M | 19.3M | 97.7M | 122M | 47.0M |
| Operating Income | -5.15M | -7.09M | -6.16M | -4.14M | -6.96M | -257K | -6.19M | 1.16M | 4.48M | 10.5M |
| EBITDA | -5.59M | -6.27M | -4.25M | -3.27M | -3.21M | 866K | -2.46M | 4.59M | 11.1M | 13.9M |
| Net Income | -5.01M | -5.97M | -3.19M | -4.19M | -4.61M | -1.19M | -4.93M | 5.26M | 13.2M | 7.34M |
| EPS | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | -0.01 | 0.01 | 0.02 | 0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 12.1M | 29.8M | 28.2M | 37.9M | 38.3M | 35.0M | 92.6M | 109M | 127M | 132M |
| Total Liabilities | 1.24M | 1.36M | 2.13M | 14.0M | 16.0M | 17.3M | 27.2M | 36.6M | 44.1M | 41.8M |
| Shareholders' Equity | 10.8M | 28.5M | 26.1M | 23.8M | 22.4M | 17.7M | 65.4M | 72.1M | 83.3M | 90.7M |
| Cash & Short-term Investments | 5.55M | 22.2M | 14.0M | 11.7M | 7.74M | 6.15M | 46.9M | 46.0M | 33.6M | 35.5M |
| Total Debt | - | - | 10.0M | 10.0M | 10.00M | 11.0M | 16.0M | 15.4M | 17.1M | 17.6M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -5.16M | -6.88M | -3.37M | -403K | -249K | -2.06M | -5.93M | 3.68M | 3.15M | 23.2M |
| Capital Expenditure | 582K | 220K | 6.52M | 8.87M | 3.57M | 492K | 1.53M | 2.90M | 13.9M | 13.8M |
| Free Cash Flow | -5.74M | -7.10M | -9.89M | -9.27M | -3.82M | -2.55M | -7.46M | 786K | -10.8M | 9.45M |
| Ratios | ||||||||||
| ROE | -46.3% | -21.0% | -12.2% | -17.6% | -20.6% | -6.7% | -7.5% | 7.3% | 15.9% | 8.1% |
| ROA | -41.5% | -20.0% | -11.3% | -11.1% | -12.0% | -3.4% | -5.3% | 4.8% | 10.4% | 5.5% |
| Net Profit Margin | -138.3% | -91.2% | -22.7% | -18.9% | -15.8% | -2.9% | -7.5% | 5.1% | 10.4% | 5.1% |
| Debt to Equity | - | - | 0.38x | 0.42x | 0.45x | 0.62x | 0.25x | 0.21x | 0.21x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Polynovo Ltd dividends
Polynovo Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 0.1429:1 on May 3, 2004.
Who owns Polynovo Ltd
- Insiders 9.97%
- Institutions 30.56%
- Public & others 59.46%
- Shares outstanding 691M
- Free float 601M
Top funds holding PNV.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 9.34M | 1.41% | - | Oct 2020 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 3.74M | 0.56% | - | Dec 2020 |
| iShares Core MSCI EAFE ETF | 3.16M | 0.48% | - | Feb 2021 |
| iShares MSCI EAFE Small Cap ETF | 2.45M | 0.37% | - | Feb 2021 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 1.48M | 0.22% | - | Oct 2020 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 813K | 0.12% | - | Nov 2020 |
| iShares Core MSCI Total International Stock ETF | 677K | 0.10% | - | Feb 2021 |
| SPDR Portfolio Developed World ex-US ETF | 639K | 0.10% | - | Feb 2021 |
| Vanguard International Stock Index-Pacific Stock Index | 593K | 0.09% | - | Jan 2021 |
| College Retirement Equities Fund-Stock Account | 591K | 0.09% | - | Dec 2020 |
Polynovo Ltd company profile
- Company name
- Polynovo Ltd
- Ticker
- PNV.AU
- ISIN
- AU000000PNV0
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 301
- Fiscal year end
- June
- Address
- 320 Lorimer Street, Port Melbourne, VIC, Australia, 3207
- Phone
- 61 3 8681 4050
- Website
- polynovo.com
About Polynovo Ltd
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, Hong Kong, and China. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn; NovoSorb MTX for burns, chronic, trauma, and surgical wounds; and hernia repair, plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Polynovo Ltd management
8- Mr. Bruce Peatey M.B.A.Chief Executive Officer
- Mr. Jan-Marcel Gielen C.A.CFO & Company Secretary
- Dr. Marthe D'OmbrainChief Scientific Officer
- Ms. Amy DemediukCompany Secretary & General Counsel
- Ms. Kimberley AxonChief People Officer
- Mr. Edward GraubartPresident of North America
- Ms. Allison Myers B.Sc.Chief Quality & Regulatory Affairs Officer
- Mr. Tyson Parker M.B.A.Chief Manufacturing & Supply Chain Officer